Allergan’s Botox Gains Continue, Pipeline Progresses Ahead Of AbbVie Merger

 
• By Mandy Jackson

Key Allergan drugs performed well in Q3 and pipeline programs are approaching milestones as AbbVie says its $63bn acquisition of the company remains on track to close early next year.

Progress, planning strategy, rise in sales or success in business concept. Future prediction and estimation with high expectations. Development and improvement. Growing graph. Hand stacking tiles. - Image
Allergan's Q3 revenue increased 3.6% to $4.05bn, beating expectations. • Source: Shutterstock

More from Earnings

More from Business